Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma. MRZ112
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Triphase Research and Development Corp
Start Date
December 1, 2016
End Date
March 31, 2020
Administered By
Duke Cancer Institute
Awarded By
Triphase Research and Development Corp
Start Date
December 1, 2016
End Date
March 31, 2020